Assignee
RESPIVERT LTD
GB·52 granted patents·12 pending applications·303 citations·filing 2012–2023
Top patents by PatentIndex Score
64 records- 0197US9624196B2Inhibitor of p38 MAP kinaseRESPIVERT LTD·Filed 2016·Granted Apr 18, 2017·15 cites·5 claims
- 0297US9108950B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitorsRESPIVERT LTD·Filed 2012·Granted Aug 18, 2015·38 cites·13 claims
- 0397US8927563B2Kinase inhibitorRESPIVERT LTD·Filed 2014·Granted Jan 6, 2015·39 cites·6 claims
- 0496US9499486B2Kinase inhibitorRESPIVERT LTD·Filed 2015·Granted Nov 22, 2016·14 cites·10 claims
- 0596US9447076B2Inhibitor of p38 map kinaseRESPIVERT LTD·Filed 2015·Granted Sep 20, 2016·16 cites·18 claims
- 0694US8975285B2P38 MAP kinase inhibitorsRESPIVERT LTD·Filed 2013·Granted Mar 10, 2015·26 cites·3 claims
- 0793US9481648B2Kinase inhibitorsRESPIVERT LTD·Filed 2014·Granted Nov 1, 2016·22 cites·24 claims
- 0892US10738032B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-i-yl) ureas as P38 mapkinase inhibitorsRESPIVERT LTD·Filed 2019·Granted Aug 11, 2020·3 cites·24 claims
- 0992US9475796B21-pyrazolyl-3-((4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitorsRESPIVERT LTD·Filed 2012·Granted Oct 25, 2016·12 cites·14 claims
- 1092US9249125B2Pyrazole derivatives as p38 MAP inhibitorsRESPIVERT LTD·Filed 2013·Granted Feb 2, 2016·30 cites·12 claims
- 1191US10266519B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitorsRESPIVERT LTD·Filed 2017·Granted Apr 23, 2019·6 cites·11 claims
- 1290US10125100B2Kinase inhibitorsRESPIVERT LTD·Filed 2017·Granted Nov 13, 2018·6 cites·4 claims
- 1389US9751837B2Kinase inhibitorsRESPIVERT LTD·Filed 2015·Granted Sep 5, 2017·6 cites·25 claims
- 1489US9724347B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitorsRESPIVERT LTD·Filed 2016·Granted Aug 8, 2017·5 cites·17 claims
- 1588US9850231B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitorsRESPIVERT LTD·Filed 2015·Granted Dec 26, 2017·5 cites·8 claims
- 1687US11208381B2Indole derivatives and their use as protein kinase inhibitorsRESPIVERT LTD·Filed 2020·Granted Dec 28, 2021·2 cites·18 claims
- 1787US9822076B2Kinase inhibitorRESPIVERT LTD·Filed 2016·Granted Nov 21, 2017·3 cites·3 claims
- 1887US9227977B2Phosphoinositide 3-kinase inhibitorsRESPIVERT LTD·Filed 2014·Granted Jan 5, 2016·4 cites·7 claims
- 1986US10238658B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitorsRESPIVERT LTD·Filed 2018·Granted Mar 26, 2019·3 cites·19 claims
- 2085US9790174B2Kinase inhibitorsRESPIVERT LTD·Filed 2016·Granted Oct 17, 2017·3 cites·2 claims
- 2185US9242960B2P38MAP kinase inhibitorsRESPIVERT LTD·Filed 2014·Granted Jan 26, 2016·6 cites·6 claims
- 2283US10669235B2Indole derivatives and their use as protein kinase inhibitorsRESPIVERT LTD·Filed 2017·Granted Jun 2, 2020·2 cites·13 claims
- 2383US10294216B2Pyrazolyl ureas as kinase inhibitorsRESPIVERT LTD·Filed 2017·Granted May 21, 2019·1 cites·13 claims
- 2483US9993478B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitorsRESPIVERT LTD·Filed 2017·Granted Jun 12, 2018·2 cites·19 claims
- 2583US9890185B2Urea derivatives useful as kinase inhibitorsRESPIVERT LTD·Filed 2014·Granted Feb 13, 2018·8 cites·18 claims
- 2683US9796742B2Kinase inhibitorsRESPIVERT LTD·Filed 2016·Granted Oct 24, 2017·2 cites·23 claims
- 2783US9771353B2Kinase inhibitors based upon N-alkyl pyrazolesRESPIVERT LTD·Filed 2014·Granted Sep 26, 2017·3 cites·19 claims
- 2883US9701670B2Pyrazolyl-ureas as kinase inhibitorsRESPIVERT LTD·Filed 2013·Granted Jul 11, 2017·10 cites·18 claims
- 2982US10072034B2Kinase inhibitorsRESPIVERT LTD·Filed 2017·Granted Sep 11, 2018·3 cites·23 claims
- 3080US2024343711A11-pyrazolyl-3- (4- ((2 -anilinopyrimidin- 4 - yl) oxy) napththalen- i - yl) ureas as p38 mapkinase inhibitorsRESPIVERT LTD·Filed 2023·Application pending·0 cites
- 3178US9321773B2CompoundsRESPIVERT LTD·Filed 2014·Granted Apr 26, 2016·2 cites·1 claims
- 3276US11634406B2Inhibitor of p38 MAP kinaseRESPIVERT LTD·Filed 2020·Granted Apr 25, 2023·0 cites·10 claims
- 3376US11142515B2Pyrazolyl-ureas as kinase inhibitorsRESPIVERT LTD·Filed 2019·Granted Oct 12, 2021·0 cites·9 claims
- 3476US9884845B2Pyrazolyl-ureas as kinase inhibitorsRESPIVERT LTD·Filed 2015·Granted Feb 6, 2018·1 cites·17 claims
- 3574US9834560B2CompoundsRESPIVERT LTD·Filed 2016·Granted Dec 5, 2017·1 cites·21 claims
- 3673US9340545B2Quinazolin-4 (3H)—one derivatives used as P13 kinase inhibitorsRESPIVERT LTD·Filed 2013·Granted May 17, 2016·1 cites·8 claims
- 3772US9771354B2Pyrazole p38 map kinase inhibitorsRESPIVERT LTD·Filed 2016·Granted Sep 26, 2017·1 cites·31 claims
- 3870US10815217B2Inhibitor of p38 MAP kinaseRESPIVERT LTD·Filed 2018·Granted Oct 27, 2020·0 cites·13 claims
- 3970US10358445B2Respiratory formulations and compounds for use thereinRESPIVERT LTD·Filed 2014·Granted Jul 23, 2019·1 cites·3 claims
- 4069US10813932B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitorsRESPIVERT LTD·Filed 2019·Granted Oct 27, 2020·0 cites·18 claims
- 4168US10045980B2Inhibitor of p38 map kinaseRESPIVERT LTD·Filed 2017·Granted Aug 14, 2018·0 cites·13 claims
- 4266US9642799B2Crystalline 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-0X0-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamideRESPIVERT LTD·Filed 2013·Granted May 9, 2017·1 cites·18 claims
- 4361US2018000830A1Inhibitors of hemopoietic cell kinase (p-59-hck) and their use in the treatment of influenza infectionRESPIVERT LTD·Filed 2017·Application pending·0 cites
- 4460US9556184B2Phosphoinositide 3-kinase inhibitorsRESPIVERT LTD·Filed 2015·Granted Jan 31, 2017·0 cites·3 claims
- 4559US2018118754A1CompoundsRESPIVERT LTD·Filed 2017·Application pending·0 cites
- 4658US10028959B2Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitorsRESPIVERT LTD·Filed 2017·Granted Jul 24, 2018·0 cites·5 claims
- 4758US9745306B22-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl) quinazolin-4(3H)-one derivatives and their use as phosphoinositide 3-kinase inhibitorsRESPIVERT LTD·Filed 2014·Granted Aug 29, 2017·0 cites·15 claims
- 4858US2016016934A1Kinase inhibitorsRESPIVERT LTD·Filed 2014·Application pending·0 cites
- 4957US2016045512A1Inhibitors of Hemopoietic Cell Kinase (P59-HCK) and Their Use in the Treatment of Influenza InfectionRESPIVERT LTD·Filed 2015·Application pending·0 cites
- 5056US2015210722A1Kinase inhibitorsRESPIVERT LTD·Filed 2013·Application pending·0 cites
Showing the top 50 of 64 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when RESPIVERT LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →